We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardinal Health (CAH) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
In the latest close session, Cardinal Health (CAH - Free Report) was down 2.96% at $204.92. The stock's change was less than the S&P 500's daily loss of 0.64%. At the same time, the Dow lost 0.59%, and the tech-heavy Nasdaq lost 0.59%.
Shares of the prescription drug distributor witnessed a gain of 2.32% over the previous month, beating the performance of the Medical sector with its gain of 1.59%, and underperforming the S&P 500's gain of 9.33%.
Analysts and investors alike will be keeping a close eye on the performance of Cardinal Health in its upcoming earnings disclosure. The company's earnings report is set to go public on April 30, 2026. The company is forecasted to report an EPS of $2.81, showcasing a 19.57% upward movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $62.4 billion, up 13.72% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $10.32 per share and revenue of $259.25 billion, which would represent changes of +25.24% and +16.48%, respectively, from the prior year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Cardinal Health. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.09% upward. Cardinal Health is currently a Zacks Rank #2 (Buy).
Digging into valuation, Cardinal Health currently has a Forward P/E ratio of 20.46. This represents a premium compared to its industry average Forward P/E of 17.11.
It is also worth noting that CAH currently has a PEG ratio of 1.36. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Medical - Dental Supplies industry held an average PEG ratio of 1.79.
The Medical - Dental Supplies industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 93, positioning it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Cardinal Health (CAH) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest close session, Cardinal Health (CAH - Free Report) was down 2.96% at $204.92. The stock's change was less than the S&P 500's daily loss of 0.64%. At the same time, the Dow lost 0.59%, and the tech-heavy Nasdaq lost 0.59%.
Shares of the prescription drug distributor witnessed a gain of 2.32% over the previous month, beating the performance of the Medical sector with its gain of 1.59%, and underperforming the S&P 500's gain of 9.33%.
Analysts and investors alike will be keeping a close eye on the performance of Cardinal Health in its upcoming earnings disclosure. The company's earnings report is set to go public on April 30, 2026. The company is forecasted to report an EPS of $2.81, showcasing a 19.57% upward movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $62.4 billion, up 13.72% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $10.32 per share and revenue of $259.25 billion, which would represent changes of +25.24% and +16.48%, respectively, from the prior year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Cardinal Health. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.09% upward. Cardinal Health is currently a Zacks Rank #2 (Buy).
Digging into valuation, Cardinal Health currently has a Forward P/E ratio of 20.46. This represents a premium compared to its industry average Forward P/E of 17.11.
It is also worth noting that CAH currently has a PEG ratio of 1.36. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Medical - Dental Supplies industry held an average PEG ratio of 1.79.
The Medical - Dental Supplies industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 93, positioning it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.